Clinical trials: Movement Abnormalities
Idiopathic Parkinson's Disease
PF-06669571 In Subjects With Idiopathic Parkinson's Disease
This study is designed to assess safety, tolerability and pharmacokinetic data for multiple doses of PF-06669571 in subjects with idiopathic Parkinson's disease.
- Trial name
- NCT02565628
- Testing
- PF-06669571
- Where
- 9 sites in United States
- Volunteers
- 20 people
- Sponsor
- Pfizer
Parkinson's Disease
Safety and Efficacy Study of Fipamezole in Treatment of Motor Dysfunctions in Parkinson's Disease
The purpose of this study is to determine whether Fipamezole is effective in the treatment of levodopa-induced dyskinesia in advanced Parkinson's disease.
- Trial name
- Fjord (NCT00559871)
- Testing
- fipamezole
- Where
- 36 sites in United States, India
- Volunteers
- 180 people
- Sponsor
- Juvantia Pharma Ltd
Parkinson's Disease (PD)
Observational Study Evaluating Robotic Spinal Mobilization in 16 Parkinson's Disease Participants. The Study Recorded Changes in Mobility, Sit-to-stand Performance, and Pain Scores After a 2-week Intervention With the BackHug Device.
The goal of this completed observational pilot study was to evaluate the immediate and short-term clinical effects of robotic spinal mobilization on motor and non-motor symptoms in community-dwelling adults with Parkinson's…
- Trial name
- NCT07384364
- Where
- United Kingdom
- Volunteers
- 19 people
- Sponsor
- Pacla Medical Limited
Parkinson's Disease
An Evaluation of the Pharmacokinetics and Pharmacodynamics of AP09004 in Patients With Parkinson's Disease
The purpose of this study is to evaluate blood level profiles of multiple oral doses of AP09004 vs. active control and to determine its safety and efficacy in Parkinson's patients.
- Trial name
- NCT00918177
- Testing
- AP09004, Carbidopa/Levodopa, immediate release
- Where
- 7 sites in Israel
- Volunteers
- 72 people
- Sponsor
- Intec Pharma Ltd.
Multiple System Atrophy
GDNF Gene Therapy for Multiple System Atrophy
The objective of this randomized, double-blinded, placebo-controlled Phase 1 investigation is to evaluate the safety and potential clinical effect of AAV2-GDNF delivered to the putamen in subjects with either a possible or…
- Trial name
- NCT04680065
- Testing
- AAV2-GDNF gene therapy
- Where
- 7 sites in United States
- Volunteers
- 9 people
- Sponsor
- Brain Neurotherapy Bio, Inc.
Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 3
A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD
The goal of this first-in-human clinical trial is to assess the safety and tolerability of four doses of a new study drug called VO659 in people with genetic disorders called spinocerebellar ataxia type 1, type 3 or Huntington's…
- Conditions
- Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 3, Huntington Disease
- Trial name
- NCT05822908
- Testing
- VO659
- Where
- 14 sites in Denmark, France and 4 more
- Volunteers
- 68 people
- Sponsor
- Vico Therapeutics B. V.
Parkinson Disease
Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and Women
The purpose of this study is to evaluate the effect of BIA 9-1067 on the cardiac repolarization in adult healthy men and women volunteers.
- Trial name
- NCT01532115
- Testing
- BIA 9-1067, moxifloxacin
- Where
- France
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Wilson Disease
Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840
This exploratory study will investigate the effects of ALXN1840 on copper balance in participants with Wilson disease (WD).
- Trial name
- NCT04573309
- Testing
- ALXN1840
- Where
- 3 sites in United States, New Zealand and 1 more
- Volunteers
- 9 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Parkinson's Disease
Open-label Investigation of the Safety and Clinical Effects of NTCELL in Patients With Parkinson's Disease
To assess the safety of xenotransplantation of NTCELL [immunoprotected (alginate-encapsulated) choroid plexus cells] in patients with Parkinson's disease, assessed over the duration of the study, by monitoring the occurrence of…
- Trial name
- NCT01734733
- Testing
- NTCELL
- Where
- New Zealand
- Volunteers
- 4 people
- Sponsor
- Living Cell Technologies
Parkinson Disease
Study to Evaluate the Safety, Tolerability, Efficacy, and PK of FHL-301 in Parkinson's Disease Patients.
This is a phase 2, double-blind, multi-center, placebo-controlled clinical study to evaluate the safety, tolerability, efficacy, and PK of FHL-301 in adult patients with early-stage PD.
- Trial name
- NCT05931484
- Testing
- Gemfibrozil
- Sponsor
- Forest Hills Lab
Essential Tremor
Safety, Efficacy, and Tolerability of NBI-827104 for the Treatment of Essential Tremor
The main objective of this study is to evaluate the efficacy, safety, and tolerability of NBI-827104 in adults with essential tremor.
- Trial name
- NCT04880616
- Testing
- NBI-827104
- Where
- Netherlands
- Volunteers
- 31 people
- Sponsor
- Neurocrine Biosciences
Wilson Disease
Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease
This is a multicenter, randomized, open-label study with an active standard-of-care comparator (penicillamine)
- Trial name
- NCT03539952
- Testing
- Penicillamine (D1-W12), TETA 4HCL (W12-60), Penicillamine (W12-W60)
- Where
- 15 sites in United States, Belgium and 7 more
- Volunteers
- 77 people
- Sponsor
- Orphalan
Pantothenate Kinase-Associated Neurodegeneration
Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration
Patients with PKAN will be treated with the iron chelator deferiprone for 18 months. Only patients who have completed the earlier study TIRCON2012V1 (NCT01741532), a double-blind placebo-controlled trial in which participants…
- Trial name
- TIRCON-EXT (NCT02174848)
- Testing
- Deferiprone oral solution
- Where
- 4 sites in United States, Germany and 2 more
- Volunteers
- 68 people
- Sponsor
- ApoPharma
Early-onset Parkinson's Disease
The Safety, Tolerability and Preliminary Efficacy of NouvNeu001 for Early-onset Parkinson's Disease
The goal of this clinical trial is to learn about the safety of NouvNeu001 injection in Early-onset Parkinson's Disease (EOPD) patients. It will also learn about the effects of NouvNeu001 treatment.
- Trial name
- NCT06608355
- Testing
- Human Dopaminergic Progenitor Cells
- Where
- China
- Volunteers
- 6 people
- Sponsor
- iRegene Therapeutics Co., Ltd.
Parkinson Disease
Unilateral and Staged Bilateral Pallidothalamic Tractotomy Using Exablate MRgFUS in Advanced Parkinson's Disease.
This study is a randomized clinical trial evaluating a focused ultrasound treatment for people with advanced Parkinson's disease (PD) who have disabling motor complications and symptoms.
- Trial name
- FREEDOM (NCT07764874)
- Testing
- Unilateral Exablate MRgFUS Pallidothalamic Tractotomy, Staged Bilateral Exablate Pallidothalamic Tractotomy, Best Medical Treatment (BMT)
- Where
- South Korea
- Volunteers
- 120 people
- Sponsor
- InSightec
Parkinson Disease
Post Marketing Surveillance And Special Surveillance for Mirapex® Tablet in Patients With Idiopathic Parkinson's Disease
The objectives of this study are to investigate issues or questions about MIRAPEX Tablets as shown below through the Post Marketing Surveillance (PMS) study upon approval.
- Trial name
- NCT02248168
- Testing
- Pramipexole
- Volunteers
- 1,449 people
- Sponsor
- Boehringer Ingelheim
Parkinson's Disease
Kinesia HomeView - Home Diary Comparison
The objective is to compare the sensitivity and test-retest reliability of Kinesia HomeView to electronic and hand-written diaries for tracking medication state in the home.
- Trial name
- NCT01920425
- Testing
- Kinesia HomeView, Hand-written diary
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Great Lakes NeuroTechnologies Inc.
Parkinson's Disease
A Randomized, Double-blind, Placebo-controlled Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JX2105 in Healthy Chinese Subjects
The purpose of the study is to evaluate the safety, tolerability after administration of single dose or multiple doses, and the pharmacokinetics (PK) of single and multiple doses of JX2105 in healthy study participants.
- Trial name
- NCT06537050
- Testing
- JX2105
- Where
- China
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Zhejiang Jingxin Pharmaceutical Co., Ltd.
Parkinson Disease
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
This study will be evaluating the safety and efficacy of insulin and glutathione in subjects with Parkinson's Disease compared to placebo.
- Trial name
- NOSE-PD (NCT05266417)
- Testing
- INS-GSH
- Where
- 4 sites in United States
- Volunteers
- 56 people
- Sponsor
- Gateway Institute for Brain Research
Parkinson's Disease
Study of IRX4204 for Treatment of Early Parkinson's Disease
This is a single site, open-label study designed to examine dopamine transporter density using [123I]β-CIT SPECT imaging before and following treatment with IRX4204 for a 30-day period in early Parkinson's disease patients.
- Trial name
- NCT02438215
- Testing
- IRX4204
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Io Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.